Summary
Pharmacy Times: The AHA Cardiovascular-Kidney-Metabolic Health Initiative highlights the need for more integrated approaches to care. How do innovative partnerships like this help address gaps in management for patients at high cardio-renal-metabolic risk?
Neerja Balachander, MBBS, PhD: Okay, thank…
Source: Pharmacy Times
AI News Q&A (Free Content)
Q1: What is the primary goal of the American Heart Association's Cardiovascular-Kidney-Metabolic (CKM) Health Initiative?
A1: The American Heart Association's CKM Health Initiative aims to enhance care through improved collaboration among healthcare professionals for patients with multiple health conditions related to cardiovascular, kidney, and metabolic health. It seeks to provide educational resources and promote early action to prevent heart attacks, heart failure, and strokes, especially for the 1 in 3 US adults at risk of these conditions.
Q2: How does the CKM Health Initiative propose to improve interdisciplinary care practices?
A2: The CKM Health Initiative encourages healthcare systems to conduct self-assessments of cardio-kidney-metabolic care readiness and adopt interdisciplinary care practices. It provides a guide for healthcare teams to evaluate and enhance their processes and encourages signing up for updates on new tools and resources aimed at integrated care solutions.
Q3: What recent survey findings highlight the awareness level of CKM syndrome among U.S. adults?
A3: A survey conducted by the Harris Poll for the American Heart Association revealed that about 90% of U.S. adults are unaware of CKM syndrome, a condition affecting nearly 90% of adults, including heart disease, kidney disease, diabetes, and obesity. Despite this low awareness, many are interested in learning more about the condition.
Q4: What are the clinical implications of poor CKM health according to recent studies?
A4: Poor CKM health can lead to premature mortality, excess morbidity, multiorgan disease, and high healthcare expenditures, primarily due to the burden of cardiovascular disease. The interconnection between cardiovascular, kidney, and metabolic disorders necessitates a comprehensive approach to risk reduction and management.
Q5: What innovative therapeutic strategies are recommended for managing CKM-related conditions?
A5: Recommended strategies include using sodium-glucose transport protein 2 inhibitors for patients with chronic kidney disease or heart failure and glucagon-like peptide 1 receptor agonists for those with uncontrolled hyperglycemia. These interventions are part of a framework to optimize cardiovascular disease risk reduction and manage CKM-related conditions effectively.
Q6: How does dysfunctional adipose tissue contribute to CKM syndrome?
A6: Dysfunctional adipose tissue, particularly visceral adiposity, can lead to inflammation and insulin resistance, contributing to the emergence of metabolic risk factors associated with CKM syndrome. This underscores the need for comprehensive management approaches targeting these underlying issues.
Q7: What role do innovative partnerships play in addressing gaps in CKM management?
A7: Innovative partnerships, such as those formed by the CKM Health Initiative, help bridge gaps in management by fostering collaboration among sponsors like Novo Nordisk, Boehringer Ingelheim, and others. These partnerships enable the development of comprehensive care strategies and resources to support healthcare providers and patients in managing CKM risks.
References:
- American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative
- About 9 in 10 haven’t heard of condition that affects nearly 90% of U.S. adults
- Cardiovascular-kidney-metabolic (CKM) health: a presidential advisory from the American Heart Association
- A multicenter initiative to improve care in cardiometabolic disease: initial report from Cardiometabolic Center Alliance (CMCA)
